Expression and clinical significance of EGF and TGF-α in chronic pancreatitis and pancreatic cancer

被引:8
作者
Hao, Chengfei [1 ]
Li, Zhonglian [1 ]
Zhang, Xibo [1 ]
Zhang, Hongtao [1 ]
Shang, Haitao [1 ]
Bao, Jianheng [1 ]
Wang, Haibo [1 ]
机构
[1] Tianjin Nankai Hosp, Dept Hepatobiliary & Pancreat Surg, 6 Changjiang Rd, Tianjin, Peoples R China
关键词
Epidermal growth factor; Transforming growth factor alpha; Pancreatitis; chronic; Pancreatic neoplasms; GROWTH-FACTOR RECEPTOR; CELL LUNG-CANCER; GEFITINIB; ADENOCARCINOMA; CHEMOTHERAPY; GENETICS; BIOLOGY; IMPACT; RISK;
D O I
10.23736/S0391-1977.17.02721-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: The purpose of this project was to investigate the expression and clinical significance of epidermal growth factor (EGF) and the transforming growth factor-alpha (TGF-alpha) in the occurrence and development of chronic pancreatitis and pancreatic cancer. METHODS: We recruited 31 patients with chronic pancreatitis, 42 with pancreatic cancer, and 20 with normal pancreas in our hospital. Chronic pancreatitis, pancreatic cancer, and normal pancreas expressed EGF and TGF-alpha mRNAs as well as EGF and TGF-alpha proteins. RESULTS: Immunofluorescence showed that EGF and TGF-alpha were expressed in chronic pancreatitis and pancreatic cancer, but the expression levels for both proteins were higher in pancreatic cancer. Variance analysis indicated that the differences in the expression levels of EGF and TGF-alpha in chronic pancreatitis, pancreatic cancer, and normal pancreas were statistically significant. The abnormally elevated expression of EGF and TGF-alpha are closely associated with the occurrence and development of chronic pancreatitis and pancreatic cancer. CONCLUSIONS: EGF and TGF-alpha have important research value as indicators to assess the progression of these conditions and provide a new basis for the clinical diagnosis.
引用
收藏
页码:253 / 258
页数:6
相关论文
共 20 条
[1]   Chronic pancreatitis [J].
Braganza, Joan M. ;
Lee, Stephen H. ;
McCloy, Rory F. ;
McMahon, Michael J. .
LANCET, 2011, 377 (9772) :1184-1197
[2]  
Brembeck FH, 2003, CANCER RES, V63, P2005
[3]   Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer [J].
Cappuzzo, F ;
Hirsch, FR ;
Rossi, E ;
Bartolini, S ;
Ceresoli, GL ;
Bemis, L ;
Haney, J ;
Witta, S ;
Danenberg, K ;
Domenichini, I ;
Ludovini, V ;
Magrini, E ;
Gregorc, V ;
Doglioni, C ;
Sidoni, A ;
Tonato, M ;
Franklin, WA ;
Crino, L ;
Bunn, PA ;
Varella-Garcia, M .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (09) :643-655
[4]   Clinical Impact of Amphiregulin Expression in Patients With Epidermal Growth Factor Receptor (EGFR) Wild-Type Nonsmall Cell Lung Cancer Treated With EGFR-Tyrosine Kinase Inhibitors [J].
Chang, Myung Hee ;
Ahn, Hee Kyung ;
Lee, Jeeyun ;
Jung, Chan-Kwon ;
Choi, Yoon-La ;
Park, Yeon Hee ;
Ahn, Jin Seok ;
Park, Keunchil ;
Ahn, Myung-Ju .
CANCER, 2011, 117 (01) :143-151
[5]   Drug therapy: EGFR antagonists in cancer treatment [J].
Ciardiello, Fortunato ;
Tortora, Giampaolo .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (11) :1160-1174
[6]   Hedgehog signaling is required for effective regeneration of exocrine pancreas [J].
Fendrich, Volker ;
Esni, Farzad ;
Garay, Maria Veronica R. ;
Feldmann, Georg ;
Habbe, Nils ;
Jensen, Jan Nygaard ;
Dor, Yuval ;
Stoffers, Doris ;
Jensen, Jan ;
Leach, Steven D. ;
Maitra, Anirban .
GASTROENTEROLOGY, 2008, 135 (02) :621-631
[7]   Effects of gefitinib on serum epidermal growth factor receptor and HER2 in patients with advanced non-small cell lung cancer [J].
Gregorc, V ;
Ceresoli, GL ;
Floriani, I ;
Spreafico, A ;
Bencardino, KB ;
Ludovini, V ;
Pistola, L ;
Mihaylova, Z ;
Tofanetti, FR ;
Ferraldeschi, M ;
Torri, V ;
Cappuzzo, F ;
Crinò, L ;
Tonato, M ;
Villa, E .
CLINICAL CANCER RESEARCH, 2004, 10 (18) :6006-6012
[8]   Genetics and biology of pancreatic ductal adenocarcinoma [J].
Hezel, Aram F. ;
Kimmelman, Alec C. ;
Stanger, Ben Z. ;
Bardeesy, Nabeel ;
DePinho, Ronald A. .
GENES & DEVELOPMENT, 2006, 20 (10) :1218-1249
[9]  
Hruban RH, 2000, CLIN CANCER RES, V6, P2969
[10]   Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations [J].
Inoue, Akira ;
Suzuki, Takuji ;
Fukuhara, Tatsuro ;
Maemondo, Makoto ;
Kimura, Yuichiro ;
Morikawa, Naoto ;
Watanabe, Hiroshi ;
Saijo, Yasuo ;
Nukiwa, Toshihiro .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (21) :3340-3346